YL529 a novel orally available multikinase inhibitor potently inhibits angiogenesis and tumour growth in preclinical models

机译：YL529一种新型的口服多激酶抑制剂在临床前模型中有效抑制血管生成和肿瘤生长

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and PurposeTargeted chemotherapy using small-molecule inhibitors of angiogenesis and proliferation is a promising strategy for cancer therapy.

机译：背景与目的使用小分子血管生成和增殖抑制剂的靶向化疗是一种有前景的癌症治疗策略。

著录项

期刊名称 British Journal of Pharmacology and Chemotherapy
作者
Youzhi Xu; Hongjun Lin; Nana Meng; Wenjie Lu; Guobo Li; Yuanyuan Han; Xiaoyun Dai; Yong Xia; Xiangrong Song; Shengyong Yang; Yuquan Wei; Luoting Yu; Yinglan Zhao;
展开▼
作者单位

展开▼
年(卷),期 2013(169),8
年度 2013
页码 1766–1780
总页数 15
原文格式 PDF
正文语种
中图分类药学;
关键词
YL529 small molecular multikinase inhibitor anti-angiogenesis anti-proliferation;

机译：YL529;小分子多激酶抑制剂;抗血管生成;抗增殖;

相似文献

外文文献
中文文献
专利

1. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models [J] . K Dredge, E Hammond, P Handley, British Journal of Cancer . 2011,第4期

机译：PG545是乙酰肝素酶和血管生成的双重抑制剂，可在临床前模型中诱导有效的抗肿瘤和抗转移功效
2. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. [J] . Wilhelm SM, Dumas J, Adnane L, International Journal of Cancer =: Journal International du Cancer . 2011,第1期

机译：Regorafenib（Bay 73-4506）：具有有效的临床前抗肿瘤活性的血管生成，基质和致癌受体酪氨酸激酶的新口服多立糖酶抑制剂。
3. Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma [J] . Zhi‐Ming Wang, Shi‐Long Zhang, Hua Yang, Cancer Medicine . 2020,第10期

机译：蒽吡喹蛋白血管生成抑制剂的疗效和安全性与表腹蛋白组合在软组织Sarcoma的临床前模型中
4. α_vβ_3 INTEGRIN-TARGETED LIPOSOMES CONTAINING DOXORUBICIN INHIBIT TUMOR GROWTH AND ANGIOGENESIS IN A SYNGENEIC MURINE MELANOMA MODEL [C] . Charles A. Wartchow, Neal E. DeChene, S. Narasimhan Danthi, Proceedings of the 29th Annual Meeting of the Controlled Release Society . 2002

机译：含阿霉素抑制肿瘤生长和血管生成的α_vβ_3整合素靶向脂质体在共性鼠黑素瘤模型中的应用
5. Briciclib (on 013105), an elF4E inhibitor, exhibits potent anti-cancer activity in various preclinical cancer models. [D] . Desai, Bina. 2015

机译：elF4E抑制剂Briciclib（在013105上）在各种临床前癌症模型中均显示出强大的抗癌活性。
6. Formononetin a novel FGFR2 inhibitor potently inhibits angiogenesis and tumor growth in preclinical models [O] . Xiao Yu Wu, Hao Xu, Zhen Feng Wu, 2015

机译：Formononetin一种新型FGFR2抑制剂在临床前模型中有效抑制血管生成和肿瘤生长
7. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models [O] . Xiao Yu Wu, Hao Xu, Zhen Feng Wu, 2015

机译：新型FGFR2抑制剂的FormononeTin，在临床前模型中效果抑制血管生成和肿瘤生长

YL529 a novel orally available multikinase inhibitor potently inhibits angiogenesis and tumour growth in preclinical models

摘要

著录项

相似文献

相关主题

期刊订阅